◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocksGILD › Revenue

Gilead Sciences Inc (GILD) Revenue 2006–TTM

DATA UPDATED 2026-07-12

Gilead Sciences Inc annual revenue for fiscal TTM was $29.7 billion, an increase of 1.0% from $29.4 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

GILD Annual Revenue

Revenue (annual)TTM → 2026-03-312025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Total Revenue$29.7B$29.4B$28.8B$27.1B$27.3B$27.3B$24.7B$22.4B$22.1B$26.1B$30.4B$32.6B$24.9B$11.2B$9.7B$8.4B$7.9B$7.0B$5.3B$4.2B$3.0B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GILD Quarterly Revenue

Revenue (quarterly)2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Total Revenue$7.0B$7.9B$7.8B$7.1B$6.7B$7.6B$7.5B$7.0B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

More GILD metrics: Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding

All GILD financial statements → Interactive GILD charts →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.